Drug intelligence / Profile preview

NVD-001

Development stage: Phase 2
Lead developer: Novadip Biosciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Surgical, Implantation

Overview

NVD-001 is an autologous, 3D tissue-engineered bone-forming product developed by Novadip Biosciences. It is derived from a patient's own adipose-derived stem cells (ASCs) using a proprietary 3M3 platform. The manufacturing process transforms these stem cells into a scaffold-free, mineralized 3D graft containing osteoblasts and a bone-like extracellular matrix. NVD-001 is designed to promote bone regeneration and fusion in complex orthopedic conditions, such as low-grade degenerative lumbar spondylolisthesis and bone non-unions. By providing a bioactive environment and viable bone-forming cells, it aims to offer a superior alternative to traditional autografts or synthetic bone substitutes without the morbidity associated with bone harvesting.

Other names: NVD001NVD-001NVD 001

Beyond the preview

Go deeper on NVD-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVD-001.

Explore the full profile